FTY720 Attenuates LPS-Induced Inflammatory Bone Loss by Inhibiting Osteoclastogenesis via the NF-κB and HDAC4/ATF Pathways
Journal of Immunology Research · 06.01.2023 · 2023 · 1-14
DOI: 10.1155/2023/8571649 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Immunology Research, erschienen am 06.01.2023. Verfasst von Chongwei Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shanxi Key Lab of Bone and Soft Tissue Injury Repair, Department of Orthopaedics, The Second Hospital of Shanxi Medical University, Taiyuan, China. Hauptthemen laut MEDLINE: Bone Resorption, Osteolysis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shanxi Province, Shanxi Scholarship Council of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Osteoclast (OC) abnormalities lead to many osteolytic diseases, such as osteoporosis, inflammatory bone erosion, and tumor-induced osteolysis. Exploring effective strategies to remediate OCs dysregulation is essential. FTY720, also known as fingolimod, has been approved for the treatment of multiple sclerosis and has anti-inflammatory and immunosuppressive effects. Here, we found that FTY720 inhibited osteoclastogenesis and OC function by inhibiting nuclear factor kappa-B (NF-κB) signaling. Interestingly, we also found that FTY720 inhibited osteoclastogenesis by upregulating histone deacetylase 4 (HDAC4) expression levels and downregulating activating transcription factor 4 (ATF4) expression levels. In vivo, FTY720 treatment prevented lipopolysaccharide- (LPS-) induced calvarial osteolysis and significantly reduced the number of tartrate-resistant acid phosphatase- (TRAP-) positive OCs. Taken together, these results demonstrate that FTY720 can inhibit osteoclastogenesis and ameliorate inflammation-induced bone loss. Which may provide evidence of a new therapeutic target for skeletal diseases caused by OC abnormalities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shanxi Key Lab of Bone and Soft Tissue Injury Repair, Department of Orthopaedics, The Second Hospital of Shanxi Medical University, Taiyuan, China.
- Department of Biochemistry, Basic Medical College, Shanxi Medical University, Taiyuan, China.
- Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
ORCID-Profile: Chongwei Chen, Sujing Zong, Zhenyu Wang, Ruijia Yang, Yanjing Guo, Yunfei Wang, Xinping Chen, Yue Li, Shaowei Wang
Förderung
- Natural Science Foundation of Shanxi Province
- Shanxi Scholarship Council of China
- National Natural Science Foundation of China
Zitieren
APA
Chen, C., Zong, S., Wang, Z., Yang, R., Guo, Y., Wang, Y., Chen, X., Li, Y., & Wang, S. (2023). FTY720 Attenuates LPS-Induced Inflammatory Bone Loss by Inhibiting Osteoclastogenesis via the NF-κB and HDAC4/ATF Pathways. Journal of Immunology Research, 2023, 1-14. https://doi.org/10.1155/2023/8571649
Vancouver
Chen C, Zong S, Wang Z, Yang R, Guo Y, Wang Y, et al. FTY720 Attenuates LPS-Induced Inflammatory Bone Loss by Inhibiting Osteoclastogenesis via the NF-κB and HDAC4/ATF Pathways. Journal of Immunology Research. 2023;2023:1-14. doi:10.1155/2023/8571649
BibTeX
@article{Chen2023,
author = {Chen, Chongwei and Zong, Sujing and Wang, Zhenyu and Yang, Ruijia and Guo, Yanjing and Wang, Yunfei and Chen, Xinping and Li, Yue and Wang, Shaowei},
title = {FTY720 Attenuates LPS-Induced Inflammatory Bone Loss by Inhibiting Osteoclastogenesis via the NF-κB and HDAC4/ATF Pathways},
journal = {Journal of Immunology Research},
year = {2023},
volume = {2023},
pages = {1--14},
doi = {10.1155/2023/8571649}
}
EUVIMED